Clinical Trial Update: Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab in various myelofibrosis-related conditions, terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatomegaly
• Myelofibrosis
• Myelofibrosis Transformation in Essential Thrombocythemia
• Polycythemia Vera Post-polycythemia Vera Myelofibrosis
• Splenomegaly

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Status: TERMINATED | Results posted: 2019-05-15